Clinical Trial Search

Primary: Number of Subjects Meeting Definition of Treatment Success at 36 Months, by a Composite of Objective and Subjective Measures — 94; 96 Participants

Primary: Pain Intensity Measure: Visual Analogue Pain Scale — 11.8; 8.8; 9.4; 10.3 score on a scale — p=0.329

Primary: Inspiratory Capacity at Rest Measured at 60 Minutes Post-dose — 1.875; 1.990 Litre (L) — p=<0.001

Primary: Change in Concussive Symptoms on the Post Concussion Symptom Scale — 9 units on a scale

Primary: Number of Women With Clinical Cure as a Measure of Efficacy — 7; 12; 7; 3 Participants — p=0.006

Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score

Primary: Presence of Fracture — 35; 16; 34; 17 Participants

Primary: Number of Participants With Clinical Signs/Symptoms Indicating TB With a Positive CST001 Assay Result as an Indication of Clinical Sensitivity — 13 Participants

Primary: Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse…

Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes for Subjects Receiving Synflorix Vaccine Co-administered With Tritanrix-HepB/Hib and Polio Sabin…

Primary: Number of Participants With Clinical Signs/Symptoms Indicating TB With a Positive CST001 Assay Result as an Indication of Clinical Sensitivity — 29 Participants

Primary: Primary Safety Endpoint: Number of Serious Adverse Events and Serious Device-related Adverse Events — 7; 0 Reports of events

Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05

Primary: Score of Asthma Control Questionnaire — -0.48; -0.27 score on a scale

Primary: Change From Baseline to Post Intervention High Frequency (HF) and Low Frequency Divided by High Frequency (LF/HF) Power Amplitude — 0.1796; 0.1507; -0.3872; 0.3731…